Gonadotropin-Releasing Hormone clinical trials
Also written GnRH.
How each study uses Gonadotropin-Releasing Hormone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Gonadotropin-Releasing Hormone studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 10 Oct 1989 · LUTREPULSE KIT · NDA 019687 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
Studies by the year they started
30 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 1994 | 1 |
| 1998 | 1 |
| 1999 | 1 |
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 3 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 28
Massachusetts General Hospital (4) · Ferring Pharmaceuticals (4) · University of Colorado, Denver (4) · Radiation Therapy Oncology Group (2) · Stephanie B. Seminara, MD (2) · University Reproductive Associates (1) · Hoffmann-La Roche (1) · University of British Columbia (1)
Often tested with
Tested in the same studies.
Paclitaxel (2) · KISS1 protein, human (2) · Gonadorelin diacetate tetrahydrate (2) · Estrogens (2) · Progesterone (2) · Chorionic Gonadotropin (2) · Androgen Receptor Antagonists (2) · Ipatasertib (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Gonadotropin-Releasing Hormone.
- Jul 2027GnRH for Luteal Support in IVF/ICSI/FET CyclesPhase 4 · University Reproductive Associates
Studies
Open first, then newest update. How each study uses Gonadotropin-Releasing Hormone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 33
- Autonomic and Renal Contributions to Hypertension With ADTRecruitingPhase 4Virginia Commonwealth UniversityNCT07848828Written as Gonadotropin Releasing Hormone Agonists (GNRH)
- Controlled Ovarian Stimulation Versus Modified Natural Cycles in Poor RespondersRecruitingPhase 4University Hospital, GhentNCT04487925Written as A single Gonadotropin-Releasing Hormone (GnRH) antagonist corifollitropin alfa (CFA) stimulation
- GnRH Therapy on Cognition in Down SyndromeRecruitingPhase 2/3Nelly PitteloudNCT04390646Written as GnRH, gonadorelin acetate
- GnRH for Luteal Support in IVF/ICSI/FET CyclesActive, not recruitingPhase 4University Reproductive AssociatesNCT02357654Written as GnRH
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingPhase 2Hoffmann-La RocheNCT04931342Written as Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
- Contributions to Hypertension With Androgen Deprivation TherapyTerminatedPhase 4University of Colorado, DenverNCT05700903Written as Gonadotropin Releasing Hormone Agonists (GNRH)
- Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic HypogonadismCompletedPhase 2Stephanie B. Seminara, MDNCT04648969Written as GnRH
- Long Acting LHRH Versus Short Acting LHRH in the Treatment of Prostate CancerCompletedNot applicableUniversity of British ColumbiaNCT00175383Written as luteinizing hormone-releasing hormone (LHRH) short acting or long acting
- Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate CancerActive, not recruitingPhase 3Radiation Therapy Oncology GroupNCT01368588Written as luteinizing hormone-releasing hormone (LHRH) agonist or antagonist
- Recall by Genotype: Neuropeptide StimulationTerminatedPhase 1Stephanie B. Seminara, MDNCT05901467Written as GnRH
- A Study to Measure Pharmacokinetic (PK) Concentrations of Gonadotropin-Releasing Hormone Delivered by the OmniPod PumpWithdrawnPhase 1Ferring PharmaceuticalsNCT07152730Written as Lutrepulse
- Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)CompletedPhase 1Massachusetts General HospitalNCT00392756Written as gonadotropin releasing hormone (GnRH)
- Studying the Effects of 7 Days of Gonadotropin Releasing Hormone (GnRH) Treatment in Men With HypogonadismCompletedPhase 1Massachusetts General HospitalNCT00493961Written as gonadotropin releasing hormone (GnRH)
- Efficacy of Prolonged GnRH Test in Male Adolescents With Postoperative HHStatus unknownNot applicableHuashan HospitalNCT05184374Written as Gonadorelin
- LutrePulse Hypogonadotropic HypogonadismCompletedPhase 3Ferring PharmaceuticalsNCT01976728Written as Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump
- Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate CancerCompletedPhase 3Radiation Therapy Oncology GroupNCT00004054Written as Luteinizing hormone releasing hormone [LHRH] agonist
- Pulsatile Gonadotropin-releasing Hormone for Infertility in Non-obese Patients With Polycystic Ovary SyndromeStatus unknownPhase 4RenJi HospitalNCT03989024Written as Gonadorelin
- Effect of a GnRH Injection on Ghrelin Concentrations in Girls With Suspected Premature PubertyCompletedNot applicableRegion Örebro CountyNCT02431416Written as Gonadotropin releasing hormone (GnRH)
- FASTR: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate CancerTerminatedPhase 2London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph'sNCT01439542Written as Luteinizing Hormone Releasing Hormone (LHRH) Agonist
- Pulsatile GnRH in Anovulatory InfertilityStatus unknownPhase 2Massachusetts General HospitalNCT00383656Written as GnRH
See all 33 studies that test Gonadotropin-Releasing Hormone →
Given beside what is tested · 29 — Gonadotropin-Releasing Hormone is usual care or a partner of the new treatment
- The COSMYC Trial (COmbined Suppression of MYC)RecruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06922318Written as Luteinizing hormone-releasing hormone (LHRH) analogue
- Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.RecruitingPhase 3MedSIRNCT06382948Written as Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analogues
- Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPCRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT07476001Written as ADT with Luteinizing hormone-releasing hormone (LHRH) analog
- Supraphysiologic Testosterone Priming Induces Darolutamide Extended ResponseRecruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT07142551Written as Luteinizing hormone-releasing hormone (LHRH) analogue
- Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate CancerRecruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06059118Written as Luteinizing hormone-releasing hormone (LHRH) analogue
- NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.TerminatedPhase 1Novartis PharmaceuticalsNCT06379217Written as Gonadotropin-releasing hormone (GnRH) analogues
- An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLASActive, not recruitingPhase 3Aragon Pharmaceuticals, Inc.NCT02531516Written as GnRH (agonist)
- A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) StudyActive, not recruitingPhase 1Novartis PharmaceuticalsNCT06531499Written as Gonadotropin-releasing hormone (GnRH) analogues
- Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of RecurringCompletedPhase 1/2NRG OncologyNCT04037254Written as Gonadotrophin Releasing Hormone
- Reprometabolic Syndrome Mediates Subfertility in ObesityActive, not recruitingNot applicableUniversity of Colorado, DenverNCT02653092Written as GnRH
- First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate CancerActive, not recruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT05189457Written as Luteinizing Hormone Releasing Hormone
- Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal WomenActive, not recruitingEarly Phase 1Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterNCT04037605Written as Gonadorelin (also known as Lutrepulse)
- Hormonal Mechanisms of Sleep Restriction - Axis StudyActive, not recruitingPhase 1Peter y. LiuNCT03142893Written as Gonadorelin
- Administration of Kisspeptin in Patients With HyperprolactinemiaCompletedPhase 2Massachusetts General HospitalNCT02956447Written as GnRH
- Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADTTerminatedPhase 3Dana-Farber Cancer InstituteNCT03777982Written as LHRH Agonist or Antagonist
- Neuropeptides in Human ReproductionCompletedPhase 1Massachusetts General HospitalNCT01952782Written as GnRH
- Kisspeptin Administration in the AdultCompletedPhase 1Massachusetts General HospitalNCT00914823Written as GnRH
- To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (Ensure)(P05690/MK-8962-001)CompletedPhase 3Organon and CoNCT00702845Written as gonadatropin releasing hormone (GnRH) antagonist (ganirelix)
- Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)Status unknownPhase 2Dana-Farber Cancer InstituteNCT03141671Written as GnRH
- Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate CancerCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT00587431Written as GnRh (Leuprolide)
Showing 20 of 29.
Codes
What other systems call Gonadotropin-Releasing Hormone · ClinicalTrials.gg INT007734
Also registered as gonadorelin (UNII 9O7312W37G · RxNorm 6384) and gonadorelin acetate (UNII 2RG1XQ1NYJ · RxNorm 204193).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.